Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 15;13:1040999. doi: 10.3389/fphar.2022.1040999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lin, Lin, Lai, Han, Fan, Tang, Mo, Su, Liang, Shang, Lv, Guo, Pang, Zhou, Zhang and Zhang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Ponatinib attenuated FFA induced Inflammatory phenotypic transformation of macrophages. (A) Flow cytometry analysis of the distribution of CD38 in BMDM cultured with FFA or BSA after treated with ponatinib or vehicle. (B) Representative overlayed histogram in (A) (C) Analysis of CD38 positive M1 macrophage ratio after FFA treatment in (A) n = 6. (D–I) mRNA levels of gene associated with inflammatory response in FFA treated BMDMs with or without ponatinib. n = 4. Statistical comparisons were performed with unpaired two-tailed Student’s t-test (C) or one-way ANOVA (D–I) followed by Bonferroni’s multiple comparisons post hoc test. Data represent mean ± SEM, **p < 0.01, ***p < 0.001 vs. BSA + DMSO. ^# p < 0.05, ^## p < 0.01, ^### p < 0.001 vs.FFA + DMSO.